Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Newly Diagnosed Astrocytoma, Grade IV”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07715097
What this trial is testing

Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma

Who this might be right for
Glioblastoma
Beijing Tricision Biotherapeutics Inc 30
Testing effectiveness (Phase 2)Study completedNCT02805179
What this trial is testing

High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma

Who this might be right for
Glioma
University of Michigan Rogel Cancer Center 26
Post-approval studies (Phase 4)Study completedNCT00686725
What this trial is testing

Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)

Who this might be right for
Glioblastoma
Merck Sharp & Dohme LLC 99
Very early researchActive Not RecruitingNCT06824662
What this trial is testing

Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas

Who this might be right for
Glioblastoma WHO Grade IV
Nader Sanai 30
Testing effectiveness (Phase 2)Study completedNCT01977677
What this trial is testing

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Who this might be right for
Adult EpendymoblastomaAdult Giant Cell GlioblastomaAdult Glioblastoma+6 more
Lawrence Recht 30
Testing effectiveness (Phase 2)WithdrawnNCT04065087
What this trial is testing

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Who this might be right for
Newly Diagnosed Glioblastoma
Genexine, Inc.
Early research (Phase 1)Looking for participantsNCT07492316
What this trial is testing

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Who this might be right for
Recurrent Medulloblastoma
University of Florida 24
Early research (Phase 1)Ended earlyNCT02530502
What this trial is testing

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

Who this might be right for
Adult Glioblastoma
Northwestern University 4
Early research (Phase 1)Looking for participantsNCT05879367
What this trial is testing

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Who this might be right for
Glioblastoma, IDH-wildtypeGlioblastomaGlioblastoma Multiforme+4 more
Orbus Therapeutics, Inc. 66
Not applicableLooking for participantsNCT07831772
What this trial is testing

REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

Who this might be right for
GlioblastomaNewly Diagnosed GlioblastomaBrain Tumor
University of Minnesota 4
Testing effectiveness (Phase 2)Study completedNCT00590681
What this trial is testing

Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme

Who this might be right for
Glioblastoma Multiforme
University of Chicago 62
Testing effectiveness (Phase 2)Study completedNCT00817284
What this trial is testing

Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

Who this might be right for
Glioblastoma Multiforme
Ulrik Lassen 60
Large-scale testing (Phase 3)Temporarily pausedNCT02546102
What this trial is testing

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Who this might be right for
Glioblastoma Multiforme
Precision Life Sciences Group 234
Not applicableLooking for participantsNCT03526822
What this trial is testing

Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.

Who this might be right for
Brain Tumor
Assistance Publique Hopitaux De Marseille 100
Not applicableStudy completedNCT00006342
What this trial is testing

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

Who this might be right for
Brain and Central Nervous System TumorsLymphoma
Duke University 19
Testing effectiveness (Phase 2)Study completedNCT00782756
What this trial is testing

Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma

Who this might be right for
Brain CancerMalignant Glioma
Memorial Sloan Kettering Cancer Center 40
Early research (Phase 1)WithdrawnNCT03480867
What this trial is testing

Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)

Who this might be right for
Glioblastoma Multiforme, Adult
McGill University Health Centre/Research Institute of the McGill University Health Centre
Early research (Phase 1)Study completedNCT00694837
What this trial is testing

Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma

Who this might be right for
Glioblastoma
Maastricht Radiation Oncology 6
Early research (Phase 1)Study completedNCT00720564
What this trial is testing

Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma

Who this might be right for
Brain and Central Nervous System Tumors
City of Hope Medical Center 18
Testing effectiveness (Phase 2)Study completedNCT01920191
What this trial is testing

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

Who this might be right for
CNS Tumor, Adult
University Hospital, Geneva 19
Next Page